Article

7 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 50, n° 4
pages 495-528 (avril 2004)
Doi : 10.1016/j.jaad.2003.12.003
Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations
 

Jashin J Wu, MD a, David B Huang, MD, MPH b, Katie R Pang, MD a, Stephen K Tyring, MD, PhD, MBA , c
a Center for Clinical Studies, Houston, Texas, USA 
b Department of Internal Medicine, Division of Infectious Diseases, Baylor College of Medicine, Houston, Texas, USA 
c Departments of Dermatology, Microbiology-Immunology, and Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA 

*Reprint requests: Stephen K. Tyring, MD, PhD, MBA, Professor of Dermatology, University of Texas Health Science Center, Houston, 2060 Space Park Dr, Ste 200, Houston, TX 77058, USA.
Abstract

Although the development of antimicrobial drugs has advanced rapidly in the past several years, such agents act against only certain groups of microbes and are associated with increasing rates of resistance. These limitations of treatment force physicians to continue to rely on prevention, which is more effective and cost-effective than therapy. From the use of the smallpox vaccine by Jenner in the 1700s to the current concerns about biologic warfare, the technology for vaccine development has seen numerous advances. The currently available vaccines for viral illnesses include Dryvax for smallpox; the combination measles, mumps, and rubella vaccine; inactivated vaccine for hepatitis A; plasma-derived vaccine for hepatitis B; and the live attenuated Oka strain vaccine for varicella zoster. Vaccines available against bacterial illnesses include those for anthrax, Haemophilus influenzae, and Neisseria meningitidis. Currently in development for both prophylactic and therapeutic purposes are vaccines for HIV, herpes simplex virus, and human papillomavirus. Other vaccines being investigated for prevention are those for cytomegalovirus, respiratory syncytial virus, parainfluenza virus, hepatitis C, and dengue fever, among many others. Fungal and protozoan diseases are also subjects of vaccine research. Among immunoglobulins approved for prophylactic and therapeutic use are those against cytomegalovirus, hepatitis A and B, measles, rabies, and tetanus. With this progress, it is hoped that effective vaccines soon will be developed for many more infectious diseases with cutaneous manifestations.

Learning objective

At the completion of this learning activity, participants should be familiar with the current and experimental vaccines and immunotherapies for infectious diseases with cutaneous manifestations.

The full text of this article is available in PDF format.

Abbreviations : AVA, CDC, CRM197 , DTaP, DTP, HbOC, HBsAg, Hib, HPV, HSV, IVIG, LACK, MMR, OspA, OspC, PA, PGA, PRP, PRP-D, PRP-OMP, rOspA, SSPE, VIG, VLP



 Funding sources: None.
Disclosure: Dr Tyring has conducted research on vaccines for vesicular stomatitis virus, herpes simplex virus, human papillomaviruses, and HIV with grants from Merck, Chiron, GlaxoSmithKline, MedImmune, and VaxGen to the University of Texas Medical Branch and the Center for Clinical Studies.



© 2004  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline